Stocks News
Editas Medicine Q4 Results: Narrower Loss, Revenue Beat Signals Genome Editing Progress
CAMBRIDGE, Mass. — February 24, 2022: Editas Medicine Inc. (NASDAQ: EDIT), the pioneering genome editing company, reported fourth-quarter 2021 financial results that...
